Insmed (INSM) Common Equity (2010 - 2026)

Insmed has reported Common Equity for 17 years, with the latest figure at $757.5 million in Q2 2026.

• On a quarterly basis, Common Equity fell 39.39% year-over-year to $757.5 million in Q2 2026; TTM through Jun 2026 was $757.5 million, a 39.39% decrease from a year earlier, with the FY2025 full-year figure at $739.0 million, up 158.95% from the prior year.
• Common Equity was $757.5 million for Q2 2026 at Insmed, up from $704.9 million in the prior quarter.
• The five-year high for Common Equity was $1.2 billion in Q2 2025, with the low at -$464.8 million in Q1 2024.
• Average Common Equity over 5 years is $235.5 million, with a median of $93.6 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 940.93% in 2024, then jumped 3119.47% in 2025.
• Over 5 years, Common Equity stood at $88.0 million in 2022, then plunged by 477.4% to -$331.9 million in 2023, then soared by 185.98% to $285.4 million in 2024, then soared by 158.95% to $739.0 million in 2025, then gained by 2.51% to $757.5 million in 2026.
• The last three Common Equity figures came in at $757.5 million (Q2 2026), $704.9 million (Q1 2026), and $739.0 million (Q4 2025), per Business Quant data.